1. Home
  2. UPLD vs NEUP Comparison

UPLD vs NEUP Comparison

Compare UPLD & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Upland Software Inc.

UPLD

Upland Software Inc.

HOLD

Current Price

$0.88

Market Cap

28.4M

Sector

Technology

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

N/A

Current Price

$4.19

Market Cap

23.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
UPLD
NEUP
Founded
2010
1996
Country
United States
United States
Employees
N/A
8
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
28.4M
23.0M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
UPLD
NEUP
Price
$0.88
$4.19
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$4.50
$21.00
AVG Volume (30 Days)
152.6K
23.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
26.17
N/A
EPS
N/A
N/A
Revenue
$74,767,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
6.95
N/A
52 Week Low
$0.88
$3.65
52 Week High
$3.90
$21.31

Technical Indicators

Market Signals
Indicator
UPLD
NEUP
Relative Strength Index (RSI) 20.46 55.39
Support Level N/A $3.99
Resistance Level $1.62 $4.56
Average True Range (ATR) 0.08 0.17
MACD -0.00 0.02
Stochastic Oscillator 6.92 66.08

Price Performance

Historical Comparison
UPLD
NEUP

About UPLD Upland Software Inc.

Upland Software Inc is a software company. It provides cloud-based software applications in three categories: Knowledge Management that provides solutions designed to help organizations capture, organize, and distribute information to employees and customers. Content Lifecycle and Workflow Automation offers solutions that support document management, compliance, and process efficiency across various industries. Digital Marketing solutions that provides tools for audience engagement, campaign management, and content distribution across digital channels.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: